20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment

Twenty years after its initial approval, trastuzumab remains a cornerstone in the treatment of patients with human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (eBC). Long-term follow-up from pivotal adjuvant trials has consistently demonstrated significant and durable improvements in survival outcomes across various risk groups and chemotherapy backbones. In parallel, trastuzumab-induced cardiotoxicity (TIC) remains overall infrequent, particularly…